Process Validation of Metformin Hydrochloride Tablet (500 mg) according to USFDA
Article Sidebar
Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Abstract
Metformin hydrochloride is an oral anti-diabetic drug from the biguanide class used mainly to treat type 2 diabetes mellitus. As per ISO 17025, Validation is the confirmation by examination and the provision of objective evidence that the particular requirements for specific intended use are fulfilled. This research aimed to study prospective process validation for Metformin Hydrochloride 500 mg tablet dosage formulation. One initial process validation with a batch size of 200 tablets was performed. Furthermore, method, equipment, and validation criteria were taken. The critical parameter involved in sifting, blending, and compression stages were identified and evaluated as per the validation master plan. The outcome indicated that this process validation data provides a high degree of assurance that the manufacturing process produces products meeting its predetermined specifications and quality attributes.
References
FDA Guidance for industry-Process Validation: General Principles and Practices (Draft Guidance) November2008.
FDA Guideline on General Principles of Process Validation-May1987.
Venkata R &Kotta K, Process Validation of Citalopram Hydro bromide Tablets: International Journal of Research in Pharmaceutical and BiomedicalSciences.
Patel V., “Process Validation : An Essential Process In Pharmaceutical Industry” http://www.pharmainfo.net, January 2010.
International Diabetes Federation, clinical Guideline Task Force. Glucose control: Oral therapy, Global Guidelines for Type 2 Diabetes Brusseles. 35-8 (2005).
Giovanna C, Francesca M, Marzia C, Naima Z, PoalaM . Development and evaluation of an in vitro method for prediction of human drug absorption II demonstration of the method suitability. European. 27:354-362 (2006).
Werner E, Bell J. The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J ChemSoc, Transactions. 121:1790–5 (1921).
Bailey CJ, Day C. Metformin: its botanical background. Practical Diabetes International. 21(3):115–7 (2004).
Alan D. The use of Medicines in the United States. IMS Institute for Healthcare Informatics (April 2011). 28 (2011).
Adegbolagun OA, Ololade OA, Osamah SE. Comparative evaluation of biopharmaceutical and chemical equivalence of some commercially evaluable brands of ciprofloxacin hydrochloride tablets. Tropical journal of pharmaceutical research. 6:737-745(2007).
Awofisayo OS, Oladoja AA, Nse E, Imo EU. Comparative Assessment of the quality control measurements of multisource ofloxacin tablets marketed in Nigeria. Dissolution Technologies. 6:20-25 (2010).
Esiomone CO, Okoye FBC, Onah BU, Nworu CS, Omeje EO. In-vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria. J.Vector Borne Dis. 45:60-65 (2008).
Pamula RB, Surender G, Reddy KVS, Ujwala P, Jyosthna G, Kumar RM. Comparative in vitro evaluation of commercial metformin HCL tablets. JITPS 1:152-157 (2010).
Chow SJ. Pharmaceutical Validation and process controls in drug development. J Drug development. 31:1195-1201 (1997)
Imad H, Ahmed BJ. Pharmaceutical Evaluation of Metformin HCl Products Available in the Jordanian Market .Jordan Journal of Pharmaceutical Sciences. 2:1-7 (2010).
Arcot RC, Chan J, Choong T ,Teeba M , Selvadurai M, Sokkalingam A. In-vitro studies and evaluation of Metformin marketed tablets-Malaysia. Journal of Applied Pharmaceutical Science. 1:214-217 (2011).
Martindale: The Complete Drug Reference, 33rd ed.;Sweetman, S.C., Ed.; Pharmaceutical Press:London, (2002).
Nicklasson F, Alderborn G. Analysis of the compression mechanics of pharmaceutical agglomerates of different porosity and composition using the Adams and Kawakita equations. Pharmaceutical research. 2000 Aug 1;17(8):949-54.
Narendra C, Srinath MS. Formulation development of oral timed-release press-coated tablets: optimization and in vivo studies. Latin American Journal of Pharmacy. 2011;30
Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F, Khan A. Orally disintegrating films: A modern expansion in drug delivery system. Saudi Pharmaceutical Journal. 2016 Sep 1;24(5):537-46.
Raka SC, Rahman A, Bodiuzzaman B. Comparative in-vitro equivalence evaluation of fexofenadine hydrochloride 120 mg generic tablets marketed in Bangladesh. Glob J Pharmaceu Sci. 2017;3:555602.
Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat NS, Montales MT, Kuriakose K, Sasapu A. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Frontiers in endocrinology. 2017 Jan 24;8:6.
Ranjana S, Nitin S, Ganesh T, Gholve SB. Development and validation of simple UV spectrophotometric method for the determination of ledipasvir in bulk form and stress degradation studies. Inventi Rapid: Pharm Analysis & Quality Assurance. 2016;3:1-5